Workshop report: Malaria vaccine development in Europe-preparing for the future

Vaccine

Volumn 33, Issue 46, 2015, Pages 6137-6144

  Viebig, Nicola K ^a   D'Alessio, Flavia ^a   Draper, Simon J ^b   Sim, B Kim Lee ^c   Mordmüller, Benjamin ^d,e   Bowyer, Paul W ^f   Luty, Adrian J F ^g,h   Jungbluth, Stefan ^a   Chitnis, Chetan E ⁱ   Hill, Adrian V S ^b   Kremsner, Peter ^d,e   Craig, Alister G ^j   Kocken, Clemens H M ^k   Leroy, Odile ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c SANARIA INC   (United States)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e Centre de Recherches Médicales de Lambaréné HÔpital Albert Schweitzer   (Gabon)

^f NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^g Faculté de Pharmacie   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ INSTITUT PASTEUR   (France)

^j LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^k BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

more..

Author keywords

Antigen discovery; Capacity building; Controlled human malaria infection; Correlates of protection; Malaria; Vaccine

Indexed keywords

MALARIA VACCINE; SUBUNIT VACCINE;

AFRICAN; ARTICLE; DRUG EFFICACY; EUROPE; EUROPEAN; HUMAN; MALARIA; NONHUMAN; NORTH AMERICAN; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL; WORKSHOP; DRUG DEVELOPMENT; EDUCATION; HEALTH; IMMUNOLOGY; ISOLATION AND PURIFICATION; PROCEDURES; TRENDS;

DRUG DISCOVERY; EDUCATION; GLOBAL HEALTH; HUMANS; MALARIA VACCINES;

EID: 84946615936     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.09.074     Document Type: Conference Paper

References (69)

1. World Health Organization World Malaria Report 2014 2014.
2. Nunes J.K., Cardenas V., Loucq C., Maire N., Smith T., Shaffer C., et al. Modeling the public health impact of malaria vaccines for developers and policymakers. BMC Infect Dis 2013, 13:295.
3. Malaria Vaccine Funders Group Malaria Vaccine Technology Roadmap 2013 2013.
4. Malaria Vaccine Funders Group Malaria Vaccine Technology Roadmap 2006 2006.
5. Sack B.K., Miller J.L., Vaughan A.M., Douglass A., Kaushansky A., Mikolajczak S., et al. Model for in vivo assessment of humoral protection against malaria sporozoite challenge by passive transfer of monoclonal antibodies and immune serum. Infect Immun 2014, 82:808-817.
6. Sauerwein R.W., Roestenberg M., Moorthy V.S. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol 2011, 11:57-64.
7. Williams A.R., Douglas A.D., Miura K., Illingworth J.J., Choudhary P., Murungi L.M., et al. Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens. PLoS Pathog 2012, 8:e1002991.
8. Duncan C.J., Hill A.V., Ellis R.D. Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy. Hum Vaccin Immunother 2012, 8:706-714.
9. Bouharoun-Tayoun H., Attanath P., Sabchareon A., Chongsuphajaisiddhi T., Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med 1990, 172:1633-1641.
10. Kapelski S., Klockenbring T., Fischer R., Barth S., Fendel R. Assessment of the neutrophilic antibody-dependent respiratory burst (ADRB) response to Plasmodium falciparum. J Leukoc Biol 2014, 96:1131-1142.
11. Osier F.H., Feng G., Boyle M.J., Langer C., Zhou J., Richards J.S., et al. Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria. BMC Med 2014, 12:108.
12. Boyle M.J., Reiling L., Feng G., Langer C., Osier F.H., Aspeling-Jones H., et al. Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria. Immunity 2015, 42:580-590.
13. Hill D.L., Eriksson E.M., Carmagnac A.B., Wilson D.W., Cowman A.F., Hansen D.S., et al. Efficient measurement of opsonising antibodies to Plasmodium falciparum merozoites. PLoS One 2012, 7:e51692.
14. Fried M., Avril M., Chaturvedi R., Fernandez P., Lograsso J., Narum D., et al. Multilaboratory approach to preclinical evaluation of vaccine immunogens for placental malaria. Infect Immun 2013, 81:487-495.
15. Miura K., Deng B., Tullo G., Diouf A., Moretz S.E., Locke E., et al. Qualification of standard membrane-feeding assay with Plasmodium falciparum malaria and potential improvements for future assays. PLoS One 2013, 8:e57909.
16. Nikolaeva D., Draper S.J., Biswas S. Toward the development of effective transmission-blocking vaccines for malaria. Expert Rev Vaccines 2015, 14:653-680.
17. Wei C.J., Boyington J.C., McTamney P.M., Kong W.P., Pearce M.B., Xu L., et al. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010, 329:1060-1064.
18. McLellan J.S., Chen M., Joyce M.G., Sastry M., Stewart-Jones G.B., Yang Y., et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013, 342:592-598.
19. Wu X., Yang Z.Y., Li Y., Hogerkorp C.M., Schief W.R., Seaman M.S., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
20. Uthaipibull C., Aufiero B., Syed S.E., Hansen B., Guevara Patino J.A., Angov E., et al. Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum. J Mol Biol 2001, 307:1381-1394.
21. Douglas A.D., Williams A.R., Knuepfer E., Illingworth J.J., Furze J.M., Crosnier C., et al. Neutralization of Plasmodium falciparum merozoites by antibodies against PfRH5. J Immunol 2014, 192:245-258.
22. Prentice R.L. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989, 8:431-440.
23. Initiative for Vaccine Research Correlates of vaccine-induced protection: methods and implications 2013.
24. Plotkin S.A. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010, 17:1055-1065.
25. RTSS Clinical Trials Partnership Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 2014, 11:e1001685.
26. RTSS Clinical Trials Partnership Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015, 386:31-45.
27. Seder R.A., Chang L.J., Enama M.E., Zephir K.L., Sarwar U.N., Gordon I.J., et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013, 341:1359-1365.
28. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012, 366:1275-1286.
29. McCarthy J.S., Griffin P.M., Sekuloski S., Bright A.T., Rockett R., Looke D., et al. Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers. J Infect Dis 2013, 208:1688-1694.
30. Herrera S., Fernandez O., Manzano M.R., Murrain B., Vergara J., Blanco P., et al. Successful sporozoite challenge model in human volunteers with Plasmodium vivax strain derived from human donors. Am J Trop Med Hyg 2009, 81:740-746.
31. Herrera S., Solarte Y., Jordan-Villegas A., Echavarria J.F., Rocha L., Palacios R., et al. Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers. Am J Trop Med Hyg 2011, 84:4-11.
32. Pollard A.J., Savulescu J., Oxford J., Hill A.V., Levine M.M., Lewis D.J., et al. Human microbial challenge: the ultimate animal model. Lancet Infect diseases 2012, 12:903-905.
33. Academy of Medical Sciences A guidance document from the Academy of Medical Sciences: Microbial Challenge Studies of Human Volunteers 2005.
34. Moorthy V.S., Diggs C., Ferro S., Good M.F., Herrera S., Hill A.V., et al. Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA. Vaccine 2009, 27:5719-5725.
35. Epstein J.E., Tewari K., Lyke K.E., Sim B.K., Billingsley P.F., Laurens M.B., et al. Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science 2011, 334:475-480.
36. Cheng Q., Lawrence G., Reed C., Stowers A., Ranford-Cartwright L., Creasey A., et al. Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines. Am J Trop Med Hyg 1997, 57:495-500.
37. Sanderson F., Andrews L., Douglas A.D., Hunt-Cooke A., Bejon P., Hill A.V. Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value. Am J Trop Med Hyg 2008, 78:878-883.
38. Duncan C.J., Draper S.J. Controlled human blood stage malaria infection: current status and potential applications. Am J Trop Med Hyg 2012, 86:561-565.
39. Roestenberg M., Bijker E.M., Sim B.K., Billingsley P.F., James E.R., Bastiaens G.J., et al. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 2013, 88:5-13.
40. Sheehy S.H., Spencer A.J., Douglas A.D., Sim B.K., Longley R.J., Edwards N.J., et al. Optimising controlled human malaria infection studies using cryopreserved parasites administered by needle and syringe. PLoS One 2013, 8:e65960.
41. Shekalaghe S., Rutaihwa M., Billingsley P.F., Chemba M., Daubenberger C.A., James E.R., et al. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 2014, 91:471-480.
42. Hodgson S.H., Juma E., Salim A., Magiri C., Kimani D., Njenga D., et al. Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Front Microbiol 2014, 5:686.
43. Mordmuller B., Supan C., Sim K.L., Gomez-Perez G.P., Salazar C.L.O., Held J., et al. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malar J 2015, 2015.
44. Engwerda C.R., Minigo G., Amante F.H., McCarthy J.S. Experimentally induced blood stage malaria infection as a tool for clinical research. Trends Parasitol 2012, 28:515-521.
45. Stanisic D.I., Liu X.Q., De S.L., Batzloff M.R., Forbes T., Davis C.B., et al. Development of cultured Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines. Malar J 2015, 14:143.
46. Sheehy S.H., Douglas A.D., Draper S.J. Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccines. Hum Vaccin Immunother 2013, 9:1831-1840.
47. Laurens M.B., Duncan C.J., Epstein J.E., Hill A.V., Komisar J.L., Lyke K.E., et al. A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines. Vaccine 2012, 30:5302-5304.
48. Roestenberg M., McCall M., Hopman J., Wiersma J., Luty A.J.F., van Gemert G.J., et al. Protection against a malaria challenge by sporozoite inoculation. New Engl J Med 2009, 361:468-477.
49. Bijker E.M., Bastiaens G.J., Teirlinck A.C., van Gemert G.J., Graumans W., van de Vegte-Bolmer M., et al. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci U S A 2013, 110:7862-7867.
50. Bijker E.M., Teirlinck A.C., Schats R., van Gemert G.J., van de Vegte-Bolmer M., van Lieshout L., et al. Cytotoxic markers associate with protection against malaria in human volunteers immunized with Plasmodium falciparum sporozoites. J Infect Dis 2014, 210:1605-1615.
51. Roestenberg M., Teirlinck A.C., McCall M.B.B., Teelen K., Makamdop K.N., Wiersma J., et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet. 2011, 377:1770-1776.
52. Roestenberg M., O'Hara G.A., Duncan C.J., Epstein J.E., Edwards N.J., Scholzen A., et al. Comparison of clinical and parasitological data from controlled human malaria infection trials. PLoS One 2012, 7:e38434.
53. Epstein J.E., Rao S., Williams F., Freilich D., Luke T., Sedegah M., et al. Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. J Infect Dis 2007, 196:145-154.
54. McCarthy J.S., Sekuloski S., Griffin P.M., Elliott S., Douglas N., Peatey C., et al. A pilot randomised trial of induced blood-stage Plasmodium falciparum infections in healthy volunteers for testing efficacy of new antimalarial drugs. PLoS One 2011, 6:e21914.
55. Hodgson S.H., Douglas A.D., Edwards N.J., Kimani D., Elias S.C., Chang M., et al. Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies. Malar J 2015, 14:33.
56. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria RTS,S Malaria Vaccine Evaluation Group. Engl J Med 1997, 336:86-91.
57. Bojang K.A., Milligan P.J., Pinder M., Vigneron L., Alloueche A., Kester K.E., et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet. 2001, 358:1927-1934.
58. Kester K.E., McKinney D.A., Tornieporth N., Ockenhouse C.F., Heppner D.G., Hall T., et al. A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naive adults. Vaccine 2007, 25:5359-5366.
59. Kester K.E., Cummings J.F., Ofori-Anyinam O., Ockenhouse C.F., Krzych U., Moris P., et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 2009, 200:337-346.
60. World Health Organization WHO Preferred Product Characteristics (PPC) for Malaria Vaccines 2014, 27.
61. Ockenhouse C.F., Sun P.F., Lanar D.E., Wellde B.T., Hall B.T., Kester K., et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis. 1998, 177:1664-1673.
62. Clyde D.F., Most H., McCarthy V.C., Vanderberg J.P. Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci. 1973, 266:169-177.
63. Clyde D.F., McCarthy V.C., Miller R.M., Hornick R.B. Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am J Med Sci 1973, 266:398-403.
64. Hoffman S.L., Goh L.M., Luke T.C., Schneider I., Le T.P., Doolan D.L., et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis. 2002, 185:1155-1164.
65. Barry A.E., Arnott A. Strategies for designing and monitoring malaria vaccines targeting diverse antigens. Front Immunol 2014, 5:359.
66. Saul A., Fay M.P. Human immunity and the design of multi-component, single target vaccines. PLoS One 2007, 2:e850.
67. White M.T., Smith D.L. Synergism from combinations of infection-blocking malaria vaccines. Malar J 2013, 12:280.
68. UNICEF Supply Division Yellow Fever Vaccine: Current Outlook. UNICEF Supply Division 2013.
69. Hendriks J., Holleman M., Hamidi A., Beurret M., Boog C. Vaccinology capacity building in Europe for innovative platforms serving emerging markets. Hum Vaccin Immunother 2013, 9:932-936.